ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2025
Antifibrotic and anti-inflammatory properties of halofuginone in a rat craniectomy model.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCranioplasty is the process of closing a defect after craniectomy using various materials. This procedure carries risks due to adhesions formed by fibrous scar tissue after craniectomy, which can lead to complications such as cerebrospinal fluid (CSF) fistula from dural damage and cerebral hematoma contusion from parenchymal damage, which can have serious consequences. Halofuginone, a low-molecular-weight molecule derived from Dichroa febrifuga, has demonstrated antifibrotic and anti-inflammatory properties by inhibiting type I collagen synthesis and the transforming growth factor-beta (TGF-β) signaling pathway. This study aimed to investigate the effects of halofuginone on fibrotic tissue formation following craniectomy in a rat model.
methodsTwenty male Wistar rats underwent bilateral frontoparietal craniectomies and were divided into two groups: a control group treated with saline and a halofuginone group receiving oral halofuginone (1 mg/kg/day) for one week post-surgery. After 30 days, histopathological and ultrastructural analyses were performed to evaluate dura mater thickness, epidural fibrosis, arachnoid involvement, and bone regeneration.
resultsHalofuginone significantly reduced dura mater thickness (19.3+-6.51 μm vs. 51.29+-14.3 μm in controls, p<0.05) and epidural fibrosis grades, with fewer arachnoid adhesions observed in the halofuginone group (p<0.05). Electron microscopy revealed fewer active fibroblasts and thinner, disorganized collagen fibers in halofuginone-treated rats, suggesting inhibition of fibroblast activity and collagen production. No significant difference in bone regeneration was observed between the groups.
conclusionThese findings indicate that halofuginone effectively reduces fibrotic tissue formation at craniectomy sites, potentially by suppressing collagen synthesis and inflammatory responses. Further studies are warranted to explore its clinical applications in preventing postoperative fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.